These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12469940)

  • 1. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.
    Henry SP; Beattie G; Yeh G; Chappel A; Giclas P; Mortari A; Jagels MA; Kornbrust DJ; Levin AA
    Int Immunopharmacol; 2002 Nov; 2(12):1657-66. PubMed ID: 12469940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.
    Henry SP; Giclas PC; Leeds J; Pangburn M; Auletta C; Levin AA; Kornbrust DJ
    J Pharmacol Exp Ther; 1997 May; 281(2):810-6. PubMed ID: 9152389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.
    Henry SP; Jagels MA; Hugli TE; Manalili S; Geary RS; Giclas PC; Levin AA
    Nucleic Acid Ther; 2014 Oct; 24(5):326-35. PubMed ID: 25093529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
    Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA
    Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
    Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.
    Henry SP; Templin MV; Gillett N; Rojko J; Levin AA
    Toxicol Pathol; 1999; 27(1):95-100. PubMed ID: 10367680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide.
    Henry SP; Monteith DK; Matson JE; Mathison BH; Loveday KS; Winegar RA; Matson JE; Lee PS; Riccio ES; Bakke JP; Levin AA
    Mutagenesis; 2002 May; 17(3):201-9. PubMed ID: 11971990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation.
    Salerno CT; Kulick DM; Yeh CG; Guzman-Paz M; Higgins PJ; Benson BA; Park SJ; Shumway SJ; Bolman RM; Dalmasso AP
    Xenotransplantation; 2002 Mar; 9(2):125-34. PubMed ID: 11897005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey.
    Galbraith WM; Hobson WC; Giclas PC; Schechter PJ; Agrawal S
    Antisense Res Dev; 1994; 4(3):201-6. PubMed ID: 7849490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
    Kahan BD; Stepkowski S; Kilic M; Katz SM; Van Buren CT; Welsh MS; Tami JA; Shanahan WR
    Transplantation; 2004 Sep; 78(6):858-63. PubMed ID: 15385805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.
    Nemunaitis J; Holmlund JT; Kraynak M; Richards D; Bruce J; Ognoskie N; Kwoh TJ; Geary R; Dorr A; Von Hoff D; Eckhardt SG
    J Clin Oncol; 1999 Nov; 17(11):3586-95. PubMed ID: 10550158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
    Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
    Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
    Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
    J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
    Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
    Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.
    Henry SP; Bolte H; Auletta C; Kornbrust DJ
    Toxicology; 1997 Jun; 120(2):145-55. PubMed ID: 9184201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation.
    Bijsterbosch MK; Rump ET; De Vrueh RL; Dorland R; van Veghel R; Tivel KL; Biessen EA; van Berkel TJ; Manoharan M
    Nucleic Acids Res; 2000 Jul; 28(14):2717-25. PubMed ID: 10908328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.
    Henry SP; Taylor J; Midgley L; Levin AA; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):473-81. PubMed ID: 9361906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits.
    Henry SP; Denny KH; Templin MV; Yu RZ; Levin AA
    Birth Defects Res B Dev Reprod Toxicol; 2004 Dec; 71(6):368-73. PubMed ID: 15617022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
    Advani R; Lum BL; Fisher GA; Halsey J; Geary RS; Holmlund JT; Kwoh TJ; Dorr FA; Sikic BI
    Invest New Drugs; 2005 Oct; 23(5):467-77. PubMed ID: 16133798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.